Jong‐Mu Sun

12.1k total citations
234 papers, 7.1k citations indexed

About

Jong‐Mu Sun is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jong‐Mu Sun has authored 234 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Pulmonary and Respiratory Medicine, 156 papers in Oncology and 49 papers in Surgery. Recurrent topics in Jong‐Mu Sun's work include Lung Cancer Treatments and Mutations (134 papers), Lung Cancer Research Studies (58 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Jong‐Mu Sun is often cited by papers focused on Lung Cancer Treatments and Mutations (134 papers), Lung Cancer Research Studies (58 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Jong‐Mu Sun collaborates with scholars based in South Korea, United States and China. Jong‐Mu Sun's co-authors include Keunchil Park, Myung‐Ju Ahn, Jin Seok Ahn, Se‐Hoon Lee, Yoon‐La Choi, Bo Mi Ku, Hyun Ae Jung, Joungho Han, Myung‐Ju Ahn and Sung Hee Lim and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jong‐Mu Sun

229 papers receiving 7.0k citations

Peers

Countries citing papers authored by Jong‐Mu Sun

Since Specialization

Citations

This map shows the geographic impact of Jong‐Mu Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jong‐Mu Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jong‐Mu Sun more than expected).

Fields of papers citing papers by Jong‐Mu Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jong‐Mu Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jong‐Mu Sun. The network helps show where Jong‐Mu Sun may publish in the future.

Co-authorship network of co-authors of Jong‐Mu Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Jong‐Mu Sun. A scholar is included among the top collaborators of Jong‐Mu Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jong‐Mu Sun. Jong‐Mu Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), Soohyun Hwang, (unknown), Boram Lee, (unknown), Hye Min Kim, (unknown), Sehhoon Park, (unknown), Jong‐Mu Sun, Jin Seok Ahn, (unknown), Yoon‐La Choi, Chang Ho Ahn, (unknown), Chan‐Young Ock, Se-Hoon Lee	1
2	Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18 2024 ·JTO Clinical and Research Reports ·(unknown), (unknown), Young Saing Kim, Keon Uk Park, Jang Ho Cho, Hong-Sik Kim, Ki Hyeong Lee, (unknown), Il Hwan Kim, Kyung Hee Lee, Gyeong‐Won Lee, Seong Yoon Yi, Byeong‐Cheol Ahn, Min-Young Lee, Hyun Ae Jung, Sehhoon Park, Jong‐Mu Sun, Jin Seok Ahn, Se‐Hoon Lee, Myung‐Ju Ahn	1
3	LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma 2024 ·Future Oncology ·Jong‐Mu Sun, Antoine Adenis, Peter C. Enzinger, Manish A. Shah, Ken Kato, Jaafar Bennouna, Toshihiko Doi, Natalyn Hawk, Li Yu, Sukrut Shah, Pooja Bhagia, Lin Shen	2
4	TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer 2024 ·Future Oncology ·Isamu Okamoto, Shoichi Kuyama, Nicolas Girard, Shun Lü, Fábio Franke, (unknown), Pongwut Danchaivijitr, Ji‐Youn Han, Jong‐Mu Sun, Shunichi Sugawara, Edward Pan, (unknown), (unknown), (unknown), Aaron Lisberg	6
5	Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer 2024 ·EBioMedicine ·Sehhoon Park, Tae Hee Hong, Soohyun Hwang, Simon Heeke, Carl M. Gay, Jiyeon Kim, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Jong Ho Cho, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Hong Kwan Kim, Lauren A. Byers, John V. Heymach, Yoon‐La Choi, Se‐Hoon Lee, Keunchil Park	22
6	Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer 2024 ·Frontiers in Oncology ·Young-Gon Kim, Boram Lee, (unknown), (unknown), Hyun Ae Jung, Jong‐Mu Sun, Se-Hoon Lee, Myung‐Ju Ahn, (unknown), Sehhoon Park, Jong Won Kim	0
7	Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B 2024 ·Cancer ·Joo-Hyun Hong, Jiyun Lee, Sehhoon Park, (unknown), Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Dong Hyun Sinn, Myung‐Ju Ahn	3
8	Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer 2023 ·Cancer ·Sehhoon Park, Yu Jung Kim, Young Joo Min, Peter G. Mortimer, Heejung Kim, Simon A. Smith, Emma Dean, Hyun Ae Jung, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Se‐Hoon Lee, Keunchil Park	15
9	Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study 2022 ·SHILAP Revista de lepidopterología ·Bo Mi Ku, (unknown), Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Yoon‐La Choi, Myung‐Ju Ahn	1
10	Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot Study 2021 ·Journal of Medical Internet Research ·Kyungmi Yang, Dongryul Oh, Jae Myoung Noh, (unknown), Jong‐Mu Sun, Hong Kwan Kim, Jae Ill Zo, Young Mog Shim, (unknown), (unknown), Young‐In Kim	21
11	A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy 2020 ·Annals of Oncology ·Seo‐Young Park, (unknown), (unknown), S.T. Kim, Jin Hyoung Kang, Byoung Chul Cho, K.H. Lee, (unknown), Jong‐Mu Sun, S.-H. Lee, Jin Seok Ahn, K. Park, Myung‐Ju Ahn	122
12	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery 2020 ·Journal of Korean Neurosurgical Society ·Min Ho Lee, Kyung Rae Cho, Jung Won Choi, Doo‐Sik Kong, Ho Jun Seol, Do‐Hyun Nam, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Jung-Il Lee	11
13	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity 2020 ·Journal for ImmunoTherapy of Cancer ·Tae Hee Hong, Hongui Cha, Joonho Shim, Boram Lee, Jongsuk Chung, Chung Lee, Nayoung K. D. Kim, Yoon‐La Choi, Soohyun Hwang, (unknown), Sehhoon Park, Hyun Ae Jung, Ji‐Yeon Kim, (unknown), Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Se‐Hoon Lee, Woong‐Yang Park	10
14	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors 2019 ·Clinical Cancer Research ·Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park, Keunchil Park, Myung‐Ju Ahn, Eui‐Cheol Shin	132
15	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC 2019 ·Journal of Thoracic Oncology ·Sehhoon Park, Hayoon Lee, Boram Lee, Se‐Hoon Lee, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park	58
16	Benefit of Targeted DNA Sequencing in Advanced Non–Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests 2019 ·Clinical Lung Cancer ·Seonggyu Byeon, Boram Lee, Woong‐Yang Park, Yoon‐La Choi, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Se‐Hoon Lee	7
17	Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer 2016 ·Cancer Research and Treatment ·Min‐Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Keunchil Park, Young Lyun Oh, Min Eui Hong, (unknown), Young-Ik Son, Chung‐Hwan Baek, Myung‐Ju Ahn	21
18	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib 2015 ·Clinical Cancer Research ·Ji Yun Lee, Jong‐Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa‐Na Song, Bo Mi Ku, Jiae Koh, (unknown), Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	28
19	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma 2015 ·Clinical Genitourinary Cancer ·(unknown), Soon Il Lee, (unknown), Se Hoon Park, Silvia Park, In Gyu Hwang, Sang‐Cheol Lee, Jong‐Mu Sun, Jeeyun Lee, Ho Yeong Lim	11
20	A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy 2013 ·Lung Cancer ·Jin Seok Ahn, Ki Hyeong Lee, Jong‐Mu Sun, Keunchil Park, Eun‐Suk Kang, Eun Kyung Cho, Dae Ho Lee, Sang‐We Kim, Gyeong‐Won Lee, Jin‐Hyoung Kang, Jong Seok Lee, Jae‐Won Lee, Myung‐Ju Ahn	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact